HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Online-Only Appendix All Versions of this Article: dc07-1188v1 dc07-1188v2 30/12/3017    most recent Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Pratley, R. E. Articles by Dejager, S. Search for Related Content PubMed PubMed Citation Articles by Pratley, R. E. Articles by Dejager, S. Social Bookmarking                What's this?

Management of Type 2 Diabetes in Treatment-Naïve Elderly Patients: Benefits and Risks of Vildagliptin Monotherapy

¹University of Vermont College of Medicine, Burlington, VT
²Dallas Diabetes and Endocrine Center, Dallas, TX
³St. Lukes-Roosevelt Hospital, New York, NY
⁴SUNY Downstate Medical Center, Brooklyn, NY
⁵Novartis Pharma AG, Basel, Switzerland
⁶Novartis Pharmaceuticals Corporation, E. Hanover, NJ

anja.schweizer{at}novartis.com

ABSTRACT

Objective: Evaluate the efficacy and safety of vildagliptin in elderly patients with type 2 diabetes.

Research Design and Methods: Efficacy data from 5 double-blind, randomized, placebo- or active-controlled trials of 24 week duration were pooled. Effects of 24-week vildagliptin monotherapy (100 mg daily) were compared in younger (<65 years, n=1231) and older (65 years, n=238) patients. Safety data from 8 controlled clinical trials of 12-week duration were pooled; AE profiles in younger (n=1890) and older (n=374) patients were compared.

Results: Mean baseline A1C and FPG were significantly lower in older (8.3±0.1% and 9.6±0.1 mmol/L, respectively; 70 years) than in younger (8.6±0.0% and 10.4±0.1 mmol/L; 50 years) patients. Despite this, the adjusted mean change from baseline (AM) in A1C was -1.2±0.1% in older and -1.0±0.0% in younger vildagliptin-treated patients (P=0.092), and the AM FPG was significantly larger in older (-1.5±0.2 mmol/L) than in younger patients (-1.1±0.1, P=0.035) patients. Body weight was significantly lower at baseline in older (83.4±1.0 kg) than in younger patients (92.0±0.6 kg) patients. Weight decreased significantly in the older subgroup (AM= -0.9±0.3 kg, P=0.007), whereas smaller, non-significant decreases occurred in younger patients (AM= -0.2±0.1 kg). AE rates were slightly higher in older than in younger subgroups, but lower among older, vildagliptin-treated subjects (63.6%) than in the pooled active comparator group (68.1%). Vildagliptin treatment did not increase AEs among older patients with mild renal impairment (62.0%). Hypoglycemia was rare (0.8%) in the elderly and no severe events occurred.

Conclusions: Vildagliptin monotherapy was effective and well tolerated in treatment-naïve elderly patients.

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?